Drug intelligence / Profile preview

PD 2244

Development stage: Preclinical
Lead developer: P2D Bioscience
Modality: Small Molecules
Administration: Oral

Overview

PD 2244 is a small molecule, centrally acting anti-inflammatory drug under development by P2D Bioscience for the oral treatment of frontotemporal dementia (FTD) and Alzheimer's disease. Its mechanism of action involves modulation of interleukin 10 (IL-10) and inhibition of tumor necrosis factor alpha (TNFα), specifically through TNFα mRNA synthesis blockade. The drug aims to reduce neuroinflammation associated with these neurodegenerative diseases. As of September 2023, it remains in preclinical development in the United States[1][3].

Targets

IL10 (Interleukin-10)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on PD 2244.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD 2244.

Explore the full profile